Palatin Technologies Gets a Buy Rating from Roth Capital

By Jason Carr

In a report issued on October 27, Michael Higgins from Roth Capital reiterated a Buy rating on Palatin Technologies (AMEX: PTN), with a price target of $1.50. The company’s shares closed on Thursday at $0.74.

According to, Higgins is ranked 0 out of 5 stars with an average return of -14.8% and a 28.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Eiger Biopharmaceuticals.

Palatin Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $6.

The company has a one-year high of $0.90 and a one-year low of $0.29. Currently, Palatin Technologies has an average volume of 2.11M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.